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1 Drug description 
Generic/Brand name/ATC code:  
Nilotinib, AMN107 / Tasigna® / L01XE08 
Developer/Company:  
Novartis Europharm Ltd 
Description:  
Nilotinib is a synthetic aminopyrimidine and an analogue of imatinib1 that 
inhibits the BCR-ABL tyrosine-kinase [1]. BCR-ABL is the oncogenic 
product of the Philadelphia (Ph+) chromosome, which is present in >90% 
of cancer cells of all adult patients suffering from chronic myeloid 
leukaemia (CML). The BCR-ABL fusion protein acts as a tyrosine- kinase 
inhibitor (TKI) mediating the development and maintenance of CML 
through interaction with multiple downstream signalling partners, resulting 
in altered cellular adhesion, activation of mitogenic signalling and 
inhibition of apoptosis, leading to the transformation of hematopoietic stem 
cells. Briefly, TKIs have the ability to significantly reduce the proliferation 
of BCR-ABL positive CML cells by inhibiting the BCR-ABL pathway [2]. 
The current standard of care in 1st-line therapy is imatinib, the first in-class 
TKI. Studies show that nilotinib is highly selective for BCR-ABL, binding to 
wild-type BCR-ABL with 10-50 times the affinity of imatinib. Further, 
nilotinib shows in vitro activity against imatinib-resistant mutants [1, 3]. 
Both, the European Medicines Agency (EMA) and the U.S. Food and Drug 
Administration (US FDA) recommend nilotinib at a dose of 400mg, 
administered orally twice a day for the treatment of CML patients in the 
chronic or accelerated phase who are intolerant or resistant to imatinib [4-5]. 
For the 1st-line therapy of Ph+ CML, the US FDA recommends 300mg 
given twice daily, whereas the EMA has not yet published a recommended 
dose of nilotinib for the 1st-line treatment of Ph+ CML [6-7]. Nilotinib 
should be administered as long as the patient continues to benefit [3]. The 
median duration of nilotinib 1st-line therapy in Ph+ CML-CP can only be 
estimated [8]. Nilotinib has to be used with caution in patients having severe 
problems with their liver or who suffer from certain heart problems [3]. 
2 Indication 
Nilotinib is indicated for the 1st-line treatment of patients with Philadelphia 
chromosome positive (Ph+) chronic myelogenous leukaemia (CML) in the 
chronic phase (CP) (Ph+ CML-CP). 
                                                             
1 Imatinib is another tyrosine kinase inhibitor (TKI), which is currently standard of 
care in the 1st-line therapy of Ph+ CML-CP. For details see Chapters 4 and 5. 
nilotinib (Tasigna®) 
 
 
Novartis Europharm Ltd 
90% of adult CML are 
Ph+ 
 
 
reduction of 
proliferation by 
inhibition of the BCR-
ABL pathway 
highly selective for BCR-
ABL 
1st-line therapy: 300mg 
twice daily 
2nd-line therapy: 400mg 
twice daily 
 
median treatment 
duration not yet known 
1st-line therapy of Ph+ 
CML-CP 
Horizon Scanning in Oncology 
4 LBI-HTA | 2011 
3 Current regulatory status 
Orphan drug designation for nilotinib was granted for the treatment of CML 
in May 2006 by the EMA. In November 2007, the European Commission 
approved Tasigna® for the treatment of adult patients with chronic phase 
and accelerated phase Ph+ CML with intolerance to prior therapy including 
imatinib. Efficacy data in patients with CML in blast crisis were not 
available [7]. 
In September 2010, EMA’s Committee for Medicinal Products for Human 
Use (CHMP) adopted a positive opinion recommending a variation to the 
terms of marketing authorisation for the medicinal product Tasigna®. The 
CHMP adopted a positive opinion to recommend nilotinib for the treatment 
of adult patients with newly diagnosed Ph+ CML-CP patients [7]. 
The US FDA approved nilotinib for the 2nd-line therapy in adult patients 
with Ph+ CML-CP in October 2007 and for the 1st-line therapy of Ph+ 
CML-CP patients in June 2010 [9]. 
4 Burden of disease 
CML is a clonal haematopoietic stem-cell disorder resulting in a 
dysregulated production and uncontrolled proliferation of mature and 
maturing granulocytes (i.e. white blood cells) [10]. CML is one of the few 
malignant diseases triggered by a single oncogene – the BCR-ABL fusion 
protein, which acts as an active kinase. Thus, kinase inhibitors such as 
imatinib, nilotinib and dasatinib are efficacious in the CML-CP therapy by 
blocking the activity of BCR-ABL [11]. CML is initially diagnosed by 
typical findings in the blood and in the bone marrow. Blood tests at 
diagnosis include a complete blood count with microscopic differential 
count, assessment of BCR-ABL mRNA transcripts, assessment of serum 
tryptase level, cytogenetic analysis, and HLA-typing [12]. Investigations for 
the staging of CML include a chest X-ray, electrocardiogram and 
echocardiogram, if needed (e.g. when a relevant co-existing cardiac disease is 
suspected). Further, depending on the clinical situation and symptoms, a 
computed tomography, neurologic tests or a lumbar puncture may be 
required. Details about diagnosis and staging are described in more detail 
elsewhere [12-14]. 
CML has basically three different stages – chronic phase, accelerated phase 
and blast crisis. The initial chronic phase (CP) can be asymptomatic and if 
left untreated the disease will progress at random to an accelerated phase 
(AP) and then to fatal blast crisis (BC) within 3 to 5 years [15]. After 2002, 
with the introduction of imatinib as 1st-line therapy in CML, the 5-year 
survival rate improved from 53% (1999-2005) to 89% [15].  
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Despite different definitions of accelerated phase and blast crisis, the phase 
of the disease strongly influences the response to therapy, the duration of the 
response and overall survival (OS) with better results for chronic phase than 
for accelerated phase and for accelerated phase than for blast crisis [16]. 
Typical symptoms of CML are fatigue, weight loss, sweating and abdominal 
discomfort from an enlarged spleen [14]. 
CML accounts for approximately 15-20% of all adult leukaemia patients [3, 
17] with a yearly incidence of 1 in 100,000 of population in Western 
countries [3]. CML is uncommon in children and accounts for less than 5% 
of all childhood leukaemias. Men are generally more often affected than 
women (3:2) and the incidence increases steadily [3] with age. Median age is 
55-66 years at time of diagnosis [2, 15]. 
Approximately 90-95% of patients are diagnosed in the CP of their disease 
[18] and more than 90% of CML patients are Philadelphia chromosome 
positive [2]. 
In the treatment management of CML, several prognostic factors have been 
identified, which can be categorised in baseline factors and response-related 
factors. Whereas baseline factors such as phase of the disease and risk scores 
(e.g.: encompassing phase of the disease, blast cell counts, basophils, spleen 
size and cytopenias [12]) can be identified prior to the treatment, response-
related factors like cytogenetic, hematologic and molecular response (CyR, 
HR, MolR) are prognostic factors that can be identified during the 
treatment of CML [16, 19]. As these prognostic factors were established 
based on efficacy data of the 1st-line treatment of CML patients with 
imatinib and recombinant interferon-alpha (rIFNα), the European 
LeukemiaNet [20] points out that these prognostic factors cannot necessarily 
be applied to nilotinib or dasatinib, two second-generation TKIs targeting 
the BCR-ABL fusion gene due to several reasons – short follow-up of 
existing studies and more rapid responses to dasatinib and nilotinib therapy 
compared to imatinib therapy, saying that if a patient has not achieved a 
CyR at 3 months or a less than minor CyR at 6 months, the probability of 
achieving a complete CyR (CCyR) later on is small. Thus, prognostic factors 
regarding the 1st-line therapy in Ph+ CML-CP with nilotinib or dasatinib 
are not yet finally established [20].  
In Austria, the overall incidence of leukaemia was 894 patients, of which 489 
are male and 405 female in 2008 [21]. Applying the above mentioned 
estimates, the incidence of newly diagnosed Ph+ CML-CP patients is 
approximately 110 per year in Austria. 
5 Current treatment 
Since December 2002, imatinib mesylate (IM) at a dose of 400mg once daily 
is approved as 1st-line therapy for CML and is currently considered to be 
standard of care in newly diagnosed CML-CP patients [14, 17, 22]. 
The motivation for treatments other than IM are intolerance or excess 
toxicity, treatment failure, development of BCR-ABL resistant mutations 
and suboptimal response [16]. Therapy options for those patients are: 
- Imatinib dose escalation to 600-800mg/kg, 
phase of disease as 
prognostic factor 
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- rIFNα, 
- chemotherapeutic drugs such as hydroxyurea , low-dose arabinosyl 
cytosine  
- or allogeneic hematopoietic stem cell transplantation (alloHSCT), 
for those patients who are eligible [14, 23]. 
Though, alloHSCT is considered to be the only possible treatment to cure 
CML, imatinib is still the 1st-line therapy of choice for CML-CP. This is 
because of transplant-associated morbidity and mortality and also because of 
limited efficacy (e.g., 5-year survival rate: 25-70% for alloHSCT vs. 6-year 
survival rate of 88% with imatinib therapy) and tolerability [11]. 
Despite the positive results of the pivotal imatinib study (IRIS), 18% of 
patients do not achieve a CCyR, approximately 10% of patients who achieve 
CCyR eventually lose their response and 4% to 8% are intolerant to 
imatinib. This results in 30-35% of patients whose outcome with imatinib is 
not optimal [22]. Some population-based series even describe an higher 
necessity for 2nd line treatments of 51% as presented at the 2010 annual 
meeting of the American Society of Hematology [24]. 
Therefore, new strategies for the treatment of imatinib intolerant or 
resistant patients need to be established. Current options for these patients 
are:  
- Higher doses of imatinib, or combination therapy  
- or the use of second-generation TKI like dasatinib, nilotinib and 
bosutinib [22]. 
In vitro and clinical study results show that these newer TKIs are generally 
more potent inhibitors of BCR-ABL kinase activity and are active against 
most imatinib-resistant tumours harbouring BCR-ABL kinase domain 
mutations. Nilotinib and dasatinib have already demonstrated high efficacy 
with a favourable toxicity profile in CML after failure of imatinib [22]. 
For both new second-generation TKIs, nilotinib and dasatinib, the CHMP 
adopted a positive opinion recommending these new agents for the 1st-line 
treatment of Ph+ CML-CP [7, 25]. 
Within the latest version of the CML clinical practice guideline of the 
National Comprehensive Cancer Network (NCCN) all three TKIs, imatinib, 
nilotinib and dasatinib, are considered to be category 12 treatment options 
for 1st-line therapy of adult patients with Ph+ CML-CP [17]. 
 
                                                             
2 Category 1 recommendation: based on high-level evidence (i.e., high-powered 
randomized clinical trials o meta-analyses), and the NCCN Guidelines Panel has 
reached uniform consensus that the recommendation is indicated. In this context, 
uniform means near unanimous positive support with some possible neutral 
positions [26]. 
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6 Evidence 
Based on a literature search, limited to the last five years, one phase III trial 
and two phase II trials evaluating the efficacy and safety of nilotinib as 1st-
line therapy in Ph+ CML-CP patients were identified. 
The phase III trial, called Evaluating Nilotinib Efficay and Safety in 
Clinical Trials- Newly Diagnosed Patients (ENESTnd), investigated in three 
treatment arms the efficacy and safety of two different dosing regimens of 
nilotinib (300mg and 400mg twice daily), both compared to imatinib 400mg 
once daily. Based on the analysis of the primary and key secondary 
endpoint, both nilotinib arms were considered to be more potent than 
imatinib. Whereas, hematologic adverse events (AEs) occurred more 
frequent in the imatinib treated group, non-hematologic AEs and laboratory 
abnormalities occurred more often in the nilotinib treated groups. The 
majority of the AEs were of grade 1 and 2 and all were considered to be 
clinically manageable [8, 27]. 
The aim of two phase II trials was to investigate the efficacy and safety of 
nilotinib 400mg in newly diagnosed Ph+ CML-CP patients. The results of 
both trials indicate that nilotinib as front-line therapy is both, clinically 
effective and safe [22, 28]. 
6.1 Efficacy and safety - Phase III studies 
Table 1: Summary of efficacy 
Study title: A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia 
Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) (ENESTnd) 
Median 14-months follow-up: Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia 
[8] 
Median 18-months follow-up: ENESTnd Update: Continued Superiority of Nilotinib Versus Imatinib in 
Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) [27] 
Study 
identifier 
ClinicalTrial.gov: NCT00471497, CAMN107A2303, EUDRACT 2007-000208-34 
randomized (1:1:1 ratio), open-label, multicenter Design 
Duration of 
main phase 
Data of the 12-month visit of the last patient randomized and 18-months 
median follow-up are available; 
Study start: July 2007; Estimated primary completion date: May 2013 
Hypothesis Superiority – 90% power to detect 15% (55% vs. 40%) increase in MMR rate for the 
nilotinib arms vs. imatinib arm  
Intervention 1 Oral nilotinib 300mg twice daily, 282 patients 
Intervention 2 Oral nilotinib 400mg twice daily, 281 patients 
Treatment 
groups 
Control Oral imatinib 400mg once daily, 283 patients 
Major molecular 
response rate 
MMR a ≥ 3.0 log reduction in BCR-ABL transcripts compared to 
the standardized baseline or ≤ 0.1 % BCR-ABL/ABL % by 
international scale as measured by RQ-PCR, confirmed by 
duplicate analysis of the same sample 
Endpoints 
and 
definitions 
[8, 20] 
Complete 
cytogenetic 
response 
CCyR 0% Ph+ metaphases 
1 phase III and 3 phase II 
trials 
ENESTnd – pivotal 
phase III trial 
nilotinib 300mg/ 
nilotinib 400mg twice 
daily vs. imatinib 
400mg once daily 
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Progression to 
accelerated 
phase (AP) or 
blast crisis (BC) 
Progression 
to AP or BC 
the time from the date of randomization to the date of 
earliest progression-defining event (limited to 
transformation to blast crisis, accelerated phase disease, 
or death from any cause). 
Time to MMR - time from the date of randomization to the date of the 
first documented MMR 
Database 
lock 
September 2, 2009 (on the basis of the 12-month visit of the last patient who underwent 
randomization [8]); ENESTnd Update: 18-months median follow-up data [27] 
Estimated primary completion date: May 2013 
Results and analysis 
Analysis 
description 
Primary analysis: intention-to-treat analysis 
Analysis 
population and 
time point 
description 
Characteristics: 846 patients with a median age of 47 years (range 18-85), Sokal risk 
group well balanced across all three study groups – low: 37% (n=310); intermediate: 
36% (n=302); high: 28% (n=234) 
Inclusion: Ph+ CML-CP as determined by conventional cytogenetic analysis of bone 
marrow, ECOG ≤2 
Exclusion: prior TKI therapy 
Treatment group Intervention 1 Intervention 2 Control 
Number of subjects 282 281 283 
MMR  
at 12 months, % 
44 
p <0.001* 
43 
p <0.001* 
22 
at 18 months, % 66 
p <0.0001* 
62 
p<0.0001* 
40 
CCyR 
at 12 months, % 
80 
p<0.001* 
78 
p<0.001* 
65 
at 18 months, % 85 
p<0.001* 
82 
p=0.017* 
74 
 
Progression to AP or BC 
at 12 months, no (%) 
2 (<1) 
p = 0.01** 
1 (<1) 
p = 0.004** 
11 (4) 
at 18 months (including 
clonal evolution), no 
(%) 
2 (0.7) 
p < 0.001** 
3 (1.2) 
p = 0.003** 
12 (4.2) 
MMR by Sokal risk score 
at 12 months, % 
low 
intermediate 
high 
 
at 18 months, % 
low 
intermediate 
high 
 
 
n.r. 
n.r. 
41 
 
 
70 
67 
59 
 
 
n.r. 
n.r. 
32 
 
 
69 
63 
51 
 
 
n.r. 
n.r. 
17 
 
 
51 
39 
28 
Median time to MMR, 
months 
8.6 11 Median not yet 
achieved 
Results 
Estimated OS rate at 18 
months, % 
98.5 
p = 0.28** 
99.3 
P = 0.03** 
96.9 
Notes  An escalation of the imatinib dose to 400 mg twice daily was permitted in 
patients who had a suboptimal response or treatment failure, as defined by 
the European LeukemiaNet [20] 
 Crossover was not permitted according to the study protocol. Instead, 
patients were eligible to participate in an extension study. 
* Cochran-Mantel-Haenszel test stratified by Sokal risk group vs imatinib 
** Log-rank test stratified by Sokal vs imatinib for time to AP/BC and OS 
n.r. – not reported 
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Table 2: Most frequent adverse events (AE) 
 ENESTnd – NCT00471497 
Grade Outcome (%) Group A (n= 279) Group B (n=277) Group C (n=280) 
Non-hematologic AEs 
All Grades Rash 31% 36% 11% 
 Headache 14% 21% 8% 
 Nausea 11% 19% 31% 
 Pruritus 15% 13% 5% 
Grade 3 or 4 Rash <1% 3% 1% 
 Headache 1% 1% 0% 
 Nausea <1% 1% 0% 
 Fatigue 0% 1% <1% 
 Vomiting 0% 1% 0% 
 Diarrhoea 1% 0% 1% 
Hematologic abnormalities 
Any grade Neutropenia 43% 38% 68% 
 Thrombocytopenia 48% 49% 56% 
 Anaemia 38% 38% 47% 
Grade 3 or 4 Neutropenia 12% 10% 20% 
 Thrombocytopenia 10% 12% 9% 
 Anaemia 3% 3% 5% 
Biochemical abnormalities 
Any grade Increased total bilirubin 53% 62% 10% 
 Increased glucose 36% 41% 20% 
 Increased ALT 66% 73% 20% 
 Increased AST 40% 48% 23% 
Grade 3 or 4 Increased total bilirubin 4% 8% <1% 
 Decreased phosphate 5% 5% 8% 
 Increased glucose 6% 4% 0% 
 Increased lipase 6% 6% 3% 
 Increased ALT 4% 9% 2% 
 
846 patients newly diagnosed with Ph+ CML-CP were randomly allocated 
to three different study groups and stratified according to the Sokal risk3 
score at time of diagnosis. Even though durable major molecular response 
rate was defined as the key secondary endpoint, the main secondary outcome 
for this publication, which reports interim results after the 12-months visit 
of the last randomized patient was CCyR. Statistically improved outcomes 
for both groups treated with nilotinib in comparison to imatinib were found 
for MMR rate and CCyR rate. 
                                                             
3 The Sokal risk score is based on age, spleen size, and peripheral-blood platelet 
count and blast count. Patients are classified as being low-risk (Sokal score, <0.8), 
intermediate-risk (0.8-1.2), or high-risk (>1.2) [8]. 
random allocation 
stratified according to 
Sokal risk score 
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Besides the above mentioned non-hematologic, hematologic AEs and 
laboratory abnormalities the following events have to be pointed out. Dose 
reductions or interruptions occurred in 59% of nilotinib 300mg group, 66% 
of the nilotinib 400mg group and in 52% of the imatinib 400mg group. All 
in all, 5%, 9% and 7% of patients of the nilotinib 300mg and 400mg groups 
and the imatinib 400mg group, respectively, discontinued the study due to 
AEs and 9 patients died until time of data cut-off at the 12-months visit of 
the last randomized patient. Within the nilotinib 300mg group, 2 patients 
died during the study (one from suicide and the other one from a small-
intestine obstruction) and one patient died during follow-up after bone 
marrow transplantation. Two patients in the nilotinib 400mg group 
discontinued treatment due to disease progression and both died during 
follow-up - one due to gastric cancer. Within the imatinib group four 
patients discontinued treatment because of disease progression and died 
during follow-up. At the 18-month median follow-up analysis, 16 patients 
had died. 11 (2, 1, 8 in the intervention 1, 2 groups and control group 
respectively) of these deaths were considered to be CML-related. 
6.2 Efficacy and safety - further studies 
Cortes et al. 2010 [22] investigated nilotinib (400mg twice daily) as 1st -line 
therapy for the treatment of early chronic phase (ECP) CML in a single-arm 
phase II study. 61 patients with a median age of 46 years were included. 
Prior to nilotinib therapy, 12 patients had received imatinib. Out of the 61 
patients, 51 had been observed for at least 3 months and were thus evaluable 
for cytogenetic and molecular response analysis. 98% of patients achieved a 
CCyR at any time, 76% achieved a MMR and 24% patients achieved a 
complete molecular response (CMR). 
Regarding AEs, the most common non-hematologic ones of grade 3-4 were 
elevations of the liver enzyme bilirubin (7%), hyperglycaemia, non-
neutropenic fever and lipase elevations (each 5%). The most common 
hematologic AEs of any grade (Grade 3-4) were neutropenia 52% (12%), 
anaemia 49% (5%) and thrombocytopenia 43% (11%). All in all, 24 patients 
(37%) required at least one treatment interruption and dose reductions were 
required in 11 patients (17%). 4 patients discontinued therapy due to 
adverse events and 2 due to progression to blast crisis. 
The GINEMA CML Working Party [28] conducted an open-label, single-
stage, multicentric phase II trial (ClinicalTrials.gov: NCT00481052) to 
investigate the safety and efficacy of 400mg nilotinib twice daily in patients 
with ECP Ph+ CML. 73 patients with a median age of 51 years were 
enrolled. At 12 months 71 patients (97%) showed complete hematologic 
response (CHR) and 70 patients (96%) had CCyR. Non-hematologic AEs of 
all grades occurring in at least 20% or patients were skin rash (grade 3: 5%), 
bone/muscle/joint pain (grade 3: 4%), headache, dry eyes, fatigue and 
pruritus (grade 3: 4%). Biochemical laboratory abnormalities occurring in at 
least 20% of patients were elevations of bilirubin (any grade: 53% / grade 3: 
16%), ALT (42% / 8%), γ-GT (36% / 7%), AST (29% / 3%) and lipase (29% 
/ 8%). Hematologic AEs (grade ≤2/3/4) were anaemia (16%/NR/NR), 
neutropenia (10/3/1%) and thrombocytopenia (1/1/1%). At least one 
temporary dose interruption is reported in 38 patients (52%) due to 
biochemical laboratory abnormalities and non-hematologic AEs [28]. After 
dose reductions more 
frequent in nilotinib 
treated pts than in 
imatinib group 
9 pts died 
98% of pts achieved 
CCyR at any time 
 
24% pts achieved CMR  
nilotinib side-effects are 
clinically manageable 
and tolerable 
at 12 months: 
97% CHR 
96% CCyR 
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30 months the overall survival, progression-free survival and failure-free 
survival were 99% and the event-free survival was 92% [29]. 
7 Estimated costs 
Currently, no price estimates are available for nilotinib in Austria. However, 
the price for one package imatinib including 30 pieces of 400mg tablets is € 
2,677 [30]. As the approved daily dose of imatinib is 400mg, monthly 
treatment costs for imatinib are around € 2,700.-. Due to expiring patents for 
imatinib, these costs are estimated to drop sharply in the near future. Like 
imatinib, nilotinib is a TKI targeting the BCR-ABL protein and is expected 
to be approved for 1st-line therapy of Ph+ CML-CP soon. Even though data 
of the pivotal ENESTnd trial indicate that nilotinib is more effective than 
imatinib, long-term follow-up data are required to compare duration of 
response and survival data of nilotinib and imatinib. Provided that their 
efficacy profile is comparable, diagnostic tests for specific BCR-ABL 
mutations might be necessary to choose the best therapy. 
Further, no data on the median duration of 1st-line nilotinib therapy are 
available yet. As imatinib is able to suppress leukemic cell growth for 
prolonged time periods but cannot eradicate the disease, life-long imatinib 
therapy appears to be required in patients responding to the therapy [12]. 
Considering that nilotinib is able to reduce the proliferation of BCR-ABL 
positive CML cells, but does not cure CML, these considerations might also 
hold true for nilotinib therapy [2]. 
8 On-going research 
By searching www.clinicaltrial.gov (search restrictions: nilotinib + phase 
III) 16 phase III trials assessing the efficacy and safety in nilotinib in 
different indications were identified. Besides 10 phase III trials of nilotinib 
as 1st- or 2nd-line therapy in CML, 5 trials for gastrointestinal stromal 
tumours (GIST) and one trial for melanoma were registered by November 
2010 at ClinicalTrials.gov [31]. 
1st-line CML therapy: 
- NCT00471497 (ENESTnd): first interim results of this pivotal 
phase III trial are presented in Chapter 6.1. The primary 
completion date is estimated to be May 2013. 
- NCT01061177 (ENEST1st): a phase IIIb, multicenter, open-label 
trail evaluating the safety and efficacy of nilotinib in adult patients 
newly diagnosed with Ph+/BCR-ABL positive CML-CP. The 
primary completion date is estimated to be December 2013. 
2nd-line CML therapy: 
- NCT00519090 (ENEST): a randomized, open-label, multicenter 
phase III study evaluating the efficacy and safety of nilotinib 
no price for nilotinib 
available in Austria 
life-long therapy? 
16 phase III trials 
assessing the efficacy 
and safety of nilotinib 
registered at 
ClinicalTrials.gov 
1st-line nilotinib in CML 
– 2 phase III studies 
registered 
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400mg twice daily compared to imatinib 400mg once daily in Ph+ 
CML-CP patients with suboptimal cytogenetic response to 
imatinib. The study has been terminated in 2009. 
- NCT00802841 (LASOR): a phase III trial evaluating the efficacy of 
nilotinib compared to imatinib in CHML patients with suboptimal 
response to standard-dose imatinib. The study started in June 2009 
and primary completion date is estimated to be March 2013. 
- NCT00760877 (ENESTcmr): a phase III open-label, randomized 
trial with the aim to determine the rate of confirmed best 
cumulative complete molecular response within the first year of 
study therapy with imatinib or nilotinib in patients with CML-CP. 
The primary completion time for the primary outcome data 
collection is November 2013. 
- NCT00905593 / NCT01126892 / NCT00786812 (ENACT): an open-
label, non-randomized multi-center phase III trial evaluating the 
long-term safety and efficacy of nilotinib in patients with imatinib 
resistant or intolerant CML in blast crisis, accelerated or chronic 
phase. It is estimated that approximately 20 patients of the ongoing 
CAMN107A2109 trial in three Mexican centers will be enrolled to 
this study. The primary completion date is estimated to be April 
2011. 
- NCT00718263: this extension study of a phase III multicenter, 
open-label randomized trial of imatinib versus nilotinib is 
evaluating the safety and efficacy of nilotinib after the failure of 
imatinib therapy or imatinib after nilotinib failure. The estimated 
primary completion date is expected to be May 2018. 
- NCT00413270: an open-label, multicenter study to evaluate the 
safety of nilotinib in CML patients with imatinib intolerance or 
resistance in all three phases – chronic, accelerated phase and blast 
crisis. Estimated completion date of this study is not mentioned. 
- NCT01126892: an open-label, multicenter phase III study 
evaluating the safety and efficacy of nilotinib in adult patients with 
Ph+ CML patients who are resistant or intolerant to imatinib. The 
primary completion date is expected to be January 2011. 
- NCT00302016: an open-label, multicenter expanded access study of 
nilotinib in adult CML patients with imatinib intolerance or 
resistance. The study has already been completed. 
Additionally to these phase III trials, several phase I and II trials evaluating 
the safety and efficacy in nilotinib in the following indications are registered 
at www.clincialtrial.gov: 
Acute myeloid leukaemia, acute lymphoblastic leukaemia, GIST, melanoma, 
acoustic neuromas (also known as vestibular schwannoma), systemic 
sclerosis, pigmented villonodular synovitis/diffuse-type giant cell 
tumour/tenosynovial giant cell tumour, malignant gliomas and non-
Hogdkin’s lymphoma. 
 
other indications: AML,  
ALL, GIST, melanoma, 
acoustic neuromas, … 
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9 Commentary 
Since 2002, imatinib is the therapy of choice for 1st-line treatment of Ph+ 
CML-CP patients. As approximately 30% to 51% of these patients develop 
resistance or are intolerant to imatinib therapy, therefore other therapy 
options are needed. Two second-generation TKIs, nilotinib and dasatinib are 
active in 2nd-line therapy of Ph+ CML-CP patients resistant or intolerant to 
imatinib and are more potent against BCR-ABL in vitro [1, 23]. The 
frequency of BCR-ABL mutations conferring resistance to TKI treatment 
seems to be higher with imatinib [32]. The efficacy and safety of both agents 
in the 1st-line therapy of Ph+ CML-CP is currently studied in ongoing 
phase III studies [1]. 
The CHMP of the EMA adopted a positive opinion recommending nilotinib 
for the 1st-line treatment of Ph+ CML-CP patients in October 2010. During 
the same meeting, the CHMP also adopted a positive opinion for the 
approval of dasatinib (Sprycel®), another 2nd -generation TKI targeting 
BCR-ABL mutations against which imatinib is resistant, for the frontline 
therapy in Ph+ CML-CP patients. Nilotinib and dasatinib are already 
approved for the 2nd-line therapy of Ph+ CML-CP patients which are 
resistant or intolerant to imatinib [25]. 
Saglio et al. (2010) conducted a phase III trial investigating whether 
nilotinib is more effective than imatinib in the 1st-line treatment of Ph+ 
CML-CP. The results of the first interim analysis at the 12-months visit of 
the last randomized patient and an update at a median follow-up at 18 
months are presented in chapter 6.1. Overall 846 patients were included in 
this study. With a median age of 47 years the study population was slightly 
younger than patients usually are at diagnosis. The surrogate endpoints 
major molecular response (MMR) and complete cytogenetic response 
(CCyR) indicate that nilotinib is more effective than imatinib with a MMR 
of 66% and 62% vs. 40%, for nilotinib 300mg, nilotinib 400mg and imatinib 
400mg, respectively. Also the key secondary endpoint (CCyR), confirmed 
the superiority of nilotinib to imatinib with a CCyR of 85% in the nilotinib 
300mg group, 82% in the nilotinib 400mg group and 74% in the imatinib 
400mg group at 12 months [33]. Progression to AP and BC was significantly 
lower in both nilotinib treated groups compared to the imatinib treated 
group with 0.7% (p=0.006) in the nilotinib 300mg group, 0.4% (p=0.003) in 
the nilotinib 400mg group and 4.2% in the imatinib 400mg group [27]. 
Whereas both drugs showed good safety profiles with the majority of AEs 
being of grade 1 or 2, some differences between nilotinib and imatinib have 
to be pointed out. The most frequent grade 3/4 AEs are neutropenia around 
11% vs. 20%, thrombocytopenia 11% vs. 9%, anaemia 3% vs. 5%, increased 
total bilirubin 6% vs. <1%, decreased phosphate 5% vs. 8%, increased 
glucose 5% vs. 0%, increased ALT 7% vs. 2% an increased AST 2% vs. 1% 
for the nilotinib groups compared to the imatinib group, respectively. The 
authors concluded that the observed AEs were clinically manageable and 
acceptable [8]. 
˜30% of pts are 
resistant or intolerant to 
imatinib 
CHMP adopted positive 
opinion to recommend 
nilotinib and dasatinib 
as 1st-line therapy in Ph+ 
CML-CP pts 
surrogate endpoints 
MMR and CCyR – both 
indicate that nilotinib is 
more effective than 
imatinib 
median age at diagnosis 
vs. pts included in the 
trial: 55-66 vs. 46-47 
years 
AE profile is considered 
to be clinically 
manageable and 
tolerable 
Horizon Scanning in Oncology 
14 LBI-HTA | 2011 
Though, the interim results of the pivotal trial indicate that nilotinib is 
more effective in the treatment of newly diagnosed Ph+ CML-CP patients, a 
few issues have to be pointed out. Hematologic response and CyR are 
considered to be surrogate endpoints reasonably likely to predict the clinical 
effectiveness in CML-CP patients [34] but the question is how these 
favourable response rates translate into progression-free survival (PFS) and 
finally into overall survival (OS). Therefore, further follow-up is essential to 
provide information on the durability of the responses, on the development 
of potential treatment resistance and to further investigate the toxicity and 
AE profile of nilotinib in the 1st-line therapy of CML [8]. 
The evaluation of the quality-of-life (QoL) of Ph+ CML-CP patients treated 
with nilotinib is another issue that needs to be investigated within clinical 
trials. Ideally, the QoL evaluation will also be conducted in patients treated 
with imatinib and dasatinib and compared to each other. 
Both, nilotinib and dasatinib have been directly compared to imatinib and 
have shown favourable results [8, 35] confirmed by a systematic review and 
meta-analysis [36]. To be able to estimate the different therapeutic effects of 
these two 2nd-generation TKIs, a head-to-head trial comparing the efficacy 
and safety of these two agents is needed. 
Currently, no price for nilotinib is available in Austria. Therefore, the costs 
of nilotinib therapy cannot be directly compared to the costs of imatinib 
therapy. As, both are TKIs targeting the BCR-ABL and are indicated for the 
treatment of Ph+ CML-CP, the monthly treatment costs can be assumed to 
be comparable until the patent of imatinib expires. 
Despite the fact that the results of the 12-month and 18-month median 
follow-up data are encouraging and are expected to have the potential to be 
at least as effective as imatinib in the frontline therapy of Ph+ CML-CP [13, 
23], mature data on PFS, OS, safety profile and QoL have to be awaited to 
confirm these estimates. 
no data on PFS or OS 
available 
 
further follow-up is 
necessary 
QoL data not yet 
available 
head-to-head 
comparison of nilotinib 
and dasatinib 
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